Technical Data
F0003-60C
FACL4 (Long-chain-fatty-acid-CoA Ligase 4, Long-chain Acyl-CoA Synthetase 4, LACS 4, ACSL4, ACS4, LACS4)
Description:
Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:128,000
Western Blot: 0.1-0.3ug/ml, observed in lysates of cell line HepG2 on ~80kD bands
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
Synthetic peptide corresponding to C-HYLKDIERMYGGK, from human ACSL4, at C-terminal (NP_004449.1, NP_075266.1).
Purity:
Purified by immunoaffinity chromatography.
Form
Supplied as a liquid in Tris saline, 0.02% sodium azide, pH 7.3, 0.5% BSA.
Specificity:
Recognizes human ACSL4. Species sequence homology: Bovine, canine, mouse, porcine and rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Piccini M, Vitelli F, Bruttini M, Pober BR, Jonsson JJ, Villanova M, Zollo M, Borsani G, Ballabio A, Renieri A. FACL4, a new gene encoding long-chain acyl-CoA synthetase 4, is deleted in a family with Alport syndrome, elliptocytosis, and mental retardation. Genomics. 1998 Feb 1;47(3):350-8.